Ashkon Software

   







 


INZY - Inozyme Pharma Inc.

Inozyme Pharma Inc. logo Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

 



 

 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer